Skip to main content
Elsevier Sponsored Documents logoLink to Elsevier Sponsored Documents
. 2020 May;142:24–38. doi: 10.1016/j.yjmcc.2020.04.001

Human Purkinje in silico model enables mechanistic investigations into automaticity and pro-arrhythmic abnormalities

Cristian Trovato a,, Elisa Passini a, Norbert Nagy b,e, András Varró b,e, Najah Abi-Gerges c, Stefano Severi d, Blanca Rodriguez a,
PMCID: PMC7294239  PMID: 32251669

Abstract

Cardiac Purkinje cells (PCs) are implicated in lethal arrhythmias caused by cardiac diseases, mutations, and drug action. However, the pro-arrhythmic mechanisms in PCs are not entirely understood, particularly in humans, as most investigations are conducted in animals. The aims of this study are to present a novel human PCs electrophysiology biophysically-detailed computational model, and to disentangle ionic mechanisms of human Purkinje-related electrophysiology, pacemaker activity and arrhythmogenicity. The new Trovato2020 model incorporates detailed Purkinje-specific ionic currents and Ca2+ handling, and was developed, calibrated and validated using human experimental data acquired at multiple frequencies, both in control conditions and following drug application. Multiscale investigations were performed in a Purkinje cell, in fibre and using an experimentally-calibrated population of PCs to evaluate biological variability. Simulations demonstrate the human Purkinje Trovato2020 model is the first one to yield: (i) all key AP features consistent with human Purkinje recordings; (ii) Automaticity with funny current up-regulation (iii) EADs at slow pacing and with 85% hERG block; (iv) DADs following fast pacing; (v) conduction velocity of 160 cm/s in a Purkinje fibre, as reported in human. The human in silico PCs population highlights that: (1) EADs are caused by ICaL reactivation in PCs with large inward currents; (2) DADs and triggered APs occur in PCs experiencing Ca2+ accumulation, at fast pacing, caused by large L-type calcium current and small Na+/Ca2+ exchanger. The novel human Purkinje model unlocks further investigations into the role of cardiac Purkinje in ventricular arrhythmias through computer modeling and multiscale simulations.

Keywords: Cardiac Purkinje, Human, Electrophysiology, Arrhythmias, In silico trials, Computer modeling

Abbreviations: AP(s), action potential(s); APA, action potential amplitude; APDx, AP duration at X% of repolarisation; BCL, basic cycle length; DAD(s), delayed after-depolarisation(s); DMP, diastolic membrane potential; dV/dtMAX, maximum upstroke velocity; EAD(s), early after-depolarisation(s); EOP, membrane potential at the end of repolarisation; GX, IX conductance; IC50, concentration for 50% channel inhibition; ICaL, L-type Ca2+ current; ICaT, T-type Ca2+ current; If, funny current; IK1, inward rectifier K+ current; IKr, rapid delayed rectifier K+ current; IKs, slow delayed rectifier K+ current; INa, fast Na+ current; INaK, Na+-K+ pump current; INaL, late Na+ current; INCX, Na+-Ca2+ exchanger current; Ito, transient outward K+ current; Isus, sustained outward K+ current; ORd, O'Hara-Rudy dynamic human ventricular model; PC(s), Purkinje cells; PRd, Pan Li-Rudy dynamic canine Purkinje model; SS, steady state; TOP, take-off potential (membrane potential before depolarisation); Trovato2020, new human cardiac Purkinje AP model; Vm, membrane potential

Graphical abstract

Unlabelled Image

Highlights

  • A human in silico AP model was developed to investigate arrhythmia in cardiac Purkinje.

  • The new Purkinje model enables multiscale investigations from single cell to tissue.

  • Populations of human Purkinje models reproduce and explain experimental variability.

  • Ca2+-current reactivation triggers EADs in virtual Purkinje cells with weak repolarisation reserve.

  • Ca2+ accumulation caused by increased Ca2+ and NCX currents triggers DADs.

1. Introduction

Cardiac Purkinje cells (PCs) play a crucial role in ventricular excitation since they guarantee a correct excitation pattern and therefore a synchronised sequence of cardiac contraction. Mounting evidence identifies PCs as an important trigger of arrhythmias [1]. Particularly, PCs may be involved in the generation of Torsade de Pointes arrhythmias [2], associated with the long QT syndrome [3], either genetic or drug-induced. Indeed, PCs obtained often from dog or rabbit hearts are a cardiac preparation commonly used for preclinical cardiotoxicity screening [4].

Purkinje and ventricular cardiomyocytes are different both in structure and electrophysiology. The main structural difference is the low density of t-tubuli in PCs [5], which induces spatial heterogeneity of Ca2+ cycling [6]. The action potential (AP) of PCs is characterised by a faster depolarisation phase, a more negative plateau and a longer AP duration (APD) compared to ventricular APs [1,7]. Due to their longer APD, PCs may be more prone than ventricular myocytes to develop pro-arrhythmic abnormalities, i.e. early and delayed after-depolarisation (EADs and DADs, respectively) [2]. Interestingly, experimental studies have reported that PCs with a less negative diastolic membrane potential (DMP) show automaticity, whereas, well-polarised PCs do not [7,8].

Isolation of PCs requires challenging procedures which make the investigation of the electrophysiological properties of PCs difficult compared to other types of cardiomyocytes [9]. Furthermore, experiments on PCs are not usually conducted in human but rather in animal models such as guinea pig, rabbit, dog, cow, sheep, all exhibiting significant interspecies differences in structure, electrophysiology and calcium handling [[10], [11], [12]]. Thus, mechanistic complexity, limited access to human tissue and experimental and ethical constraints impair our understanding of the ionic mechanisms and contribution to human arrhythmias of the Purkinje system.

The goals of our study are to integrate current knowledge on human PC electrophysiology through the development of the novel computational Trovato2020 model, and to investigate mechanisms of pro-arrhythmic abnormalities in human PC through cellular and tissue simulation studies. Human Purkinje voltage-clamp data [9], novel and partly published AP measurements [13], as well as information from the literature were used to develop, calibrate and validate the Trovato2020 model. The model structure incorporates Purkinje-specific ionic currents and a detailed Ca2+ subsystem, as in a recently published canine model (PRd, [14]), which were not considered in previously published human Purkinje-based computational models (STW [15]; TT08 [16]; SMP [17]). Simulations with the new Trovato2020 model: i) reproduce experimental recordings in a wide range of protocols as well as electrophysiological alterations following selective hERG and Ca2+ channels blocks; ii) explain the ionic mechanisms underlying pro-arrhythmic abnormalities and automaticity. Biological variability was also studied through the construction and evaluation of a populations of models [18,19] to investigate and explain the mechanisms underlying EADs, DADs and triggered activity in human Purkinje cardiomyocytes. Electrical propagation was successfully simulated in a human Purkinje fibre. The Trovato2020 model is available on the CellML repository (www.cellml.org) as well as in several formats (Matlab, C++ and Fortran) in the Oxford Computational Cardiovascular Science Team website (www.cs.ox.ac.uk/ccs).

2. Materials and methods

2.1. Experimental data

Three different experimental datasets were used in this study for calibration, optimisation and validation of the novel human cardiac Purkinje electrophysiology Trovato2020 model:

  • Dataset I. Ionic current recordings from [9]. These consist of the I-V curves for the transient and sustained outward potassium currents (Ito and Isus, respectively) and for the inward potassium rectifier current (IK1), as well as Ito steady state inactivation/activation curves, and inactivation time constants. Data were acquired from n = 20 PCs isolated from free-running false tendons from N = 9 failing human hearts.

  • Dataset II. AP recordings from n = 17 Purkinje fibres from N = 7 undiseased human hearts, acquired at multiple frequencies - basic cycle length (BCL) from 400 to 5000 ms - partly published in [13]. AP recordings were analysed to extract the following 9 biomarkers: maximum upstroke velocity (dV/dtMAX); AP duration (APD) at 90%, 75%, 50%, 25% and 10% of repolarisation (APD90, APD75, APD50, APD25, APD10); AP Amplitude (APA); membrane potential before depolarisation (TOP, take-off potential); membrane potential at the end of repolarisation (EOP, end of potential). Table 1 shows the minimum and maximum experimental values for each biomarker and BCL. A graphical visualisation of the data is presented in Fig. S1 (Supplementary Material).

  • Dataset III. AP recordings from n = 3 Purkinje fibres from N = 3 undiseased human hearts obtained with the same procedures used for ventricular trabeculae described previously [20]. 30 consecutive APs for each fibre were recorded at 1 and 2 Hz under control conditions (DMSO 0.1%), and with 100 nM dofetilide.

Table 1.

Experimental AP biomarkers.

BCL (ms)
400
500
700
1000
1500
2000
3000
5000
Min Max Min Max Min Max Min Max Min Max Min Max Min Max Min Max
dV/dtMax (V/s) 242 576 176 674 176 644 154 688 195 605 195 625 195 625 151 625
APD90 (ms) 167 288 173 338 175 389 187 438 177 445 178 415 179 470 180 497
APD75 (ms) 146 253 150 298 151 346 166 384 155 394 157 371 157 421 159 453
APD50 (ms) 114 199 118 246 121 292 124 349 122 339 127 292 125 365 129 392
APD25 (ms) 32 137 39 148 45 167 31 185 34 209 20 147 19 218 25 226
APD10 (ms) 2 65 1.4 63 1 82 1 107 1 75 1 23 1 86 1 91
APA (mV) 101 115 101 115 91 115 93 116 93 122 92 115 94 123 89 115
TOP (mV) −88 −80 −89 −75 −90 −76 −91 −79 −92 −77 −87 −76 −93 −77 −88 −73
EOP (mV) −91 −85 −89 −79 −90 −75 −94 −81 −93 −77 −89 −77 −93 −77 −88 −72

Minimum and maximum experimental values for the 9 AP biomarkers recorded in human cardiac Purkinje cells at multiple BCL: 400 ms (n = 7), 500 ms (n = 7), 700 ms (n = 9), 1000 (n = 17), 1500 ms (n = 9), 2000 ms (n = 7), 3000 (n = 8), 5000 ms (n = 8).

BCL: Basic cycle length; dV/dtMAX: maximum upstroke velocity; APDx: AP duration at X% of repolarisation; APA: action potential amplitude; TOP: membrane potential before depolarisation; EOP: membrane potential at the end of repolarisation.

As explained below, Datasets I and II were used for model development and calibration, while Dataset III was used exclusively for model validation.

2.2. Strategy for model design, calibration and validation

Fig. 1A illustrates the design, calibration, optimisation, and validation of the Trovato2020 model, described in more detail below and in the Supplementary Material, Section 1. The Trovato2020 model presented in this study was built based on the ionic formulations of the O'Hara-Rudy human ventricular model, ORd [21], and the Purkinje-specific Ca2+ sub-system, cellular compartments and intracellular ionic fluxes of the canine Purkinje AP model, PRd [14], also used by Britton et al. [19]. Fig. 1B reports a diagrammatic representation of the model structure. In brief, the Trovato2020 model includes the ORd mathematical formulation for each of the following currents: fast Na+ current (INa), Na+ late component (INaL), L-type Ca2+ current (ICaL), rapid and slow delayed K+ rectifiers (IKr and IKs, respectively), Na+-Ca2+ exchanger (INCX) and Na+-K+ pump (INaK). Ito, Isus and IK1 were formulated based on the Dataset I. In addition, two Purkinje-specific currents from the PRd model were included: T-type Ca2+ current (ICaT) and funny current (If). Existing knowledge from the literature on the ionic current differences between ventricular and PCs, and between human and canine PCs, was also taken into account.

Fig. 1.

Fig. 1

A) Schematic representation of the human Purkinje model development strategy. Blue: model development stages; green: data processing for calibration and optimisation; yellow: sensitivity analysis; orange: criteria for model development; purple: model validation and applications; red hearts: experimental datasets. B) Main structure and ionic currents of the Trovato2020 Purkinje AP model. The intracellular space is represented with 3 different compartments: peripheral coupling subspace (SS), sub-sarcolemma (SL), and bulk myoplasm (MYO). The sarcoplasmic reticulum (SR) also consists of 3 compartments: junctional (JSR), network (NSR), and corbular (CSR). 18 dynamic current models are included for Na+ (blue), K+ (purple) and Ca2+ (brown) channels, Na+-K+ pump, and Na+-Ca2+ exchanger (yellow). Intracellular Ca2+ release and up-take fluxes (green) are distributed across the 3 SR compartments. Ca2+ buffers are shown as blue clouds. Global CaMKII phosphorylation is also included, and the affected currents are marked by a spiky circle. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

The Trovato2020 model was developed to fulfil the following 6 criteria:

  • 1)

    Consistency with the experimental AP biomarkers at all BCLs: simulated values had to be within the experimental ranges shown in Table 1.

  • 2)

    APD90 rate-dependence: APD90 increase for BCLs between 400 ms and 2000 ms.

  • 3)

    APD90 changes induced by ICaL modulation: APD90 increase/shortening in response to ICaL up/down regulation. The effect of ICaL on APD90 has been shown experimentally, using selective Ca2+ blockers such as diltiazem [22] and nifedipine [23], i.e., ICaL reduction induces AP shortening, whereas ICaL increase leads to AP prolongation. Due to the lack of quantitative information and human data, we only imposed a positive correlation between changes in APD90 (∆APD90) and ICaL up/down regulation (|∆APD90| > 0.5% with ±30% ICaL).

  • 4)

    APD90 prolongation induced by IKr block. Experimental studies by [24] showed IKr block led to a longer APD in Purkinje than in ventricular cardiomyocytes. Thus, during calibration, we imposed the APD using the Trovato2020 model to be longer than the one obtained using the ventricular ORd model for both 30% and 50% IKr block.

  • 5)

    Ability to generate EADs, reported experimentally in canine PCs [25,26].

  • 6)

    Ability to generate DADs and/or triggered APs, as reported for canine PCs [27,28].

Starting from the initial model described above, a sensitivity analysis was performed to investigate how properties relevant to the 6 criteria were affected by variations in the ionic current parameters, and to guide the definition of a calibrated model (details in the Supplementary material, Section 1 and Fig. S2-S3). Parameter optimisation was then performed using a multi-objective genetic algorithm [29]. The conductances of the main currents, namely INa, INaL, ICaL, ICaT, Ito, Isus, IKr, IKs, If, IK1, INCX, INaK, as well as 7 parameters for ICaL and IKr kinetics were allowed to vary in the ranges reported in Table S1, building on the sensitivity analysis results. The algorithm was run for 30 generations, with 300 models each. The multi-object cost function was computed as a weighted sum of 2 error functions accounting for the criteria listed above (details in the Supplementary Material, Section S1.3, Table S1).

The optimised Trovato2020 model was evaluated against Dataset III, and on its ability to develop automaticity under specific conditions (details in Section 2.3).

A population of models was generated using the optimised Trovato2020 model as baseline, to reproduce the experimental variability observed in Dataset II, and to evaluate model stability to parameter variations (details in Section 2.4). Propagation of electrical excitation in a 1D fibre using the optimised Trovato2020 model was also simulated, to verify conduction velocity (CV) in control conditions, as well as to test the potential propagation of spontaneous APs, EADs and DADs in tissue, and to evaluate the effects of INa block on CV (details in the Supplementary Material, Section 1.4).

2.3. Model validation

The optimised model was evaluated against the experimental Dataset III, not considered during the model development and not used for the calibration and optimisation of the initial model. The simulations in control conditions and with dofetilide were conducted in similar experimental conditions as for Dataset III, following the protocols 1 and 7 (Section 2.5), respectively.

Moreover, the potential for automaticity was investigated using the protocol outlined below (Section 2.5), by modifying the balance between IK1 and If, which determined the DMP [2,7]. Furthermore, the effect of hyperkalaemia was also investigated by increasing the extracellular potassium concentration, since it has been shown to suppress automaticity in human PCs [8].

2.4. Population of models

Using the optimised model as baseline, we constructed a population of human Purkinje models, based on the methodology described in [18,19]. This allowed to simulate the variability in AP morphology observed in the experimental recordings (Table 1).

An initial population of 3000 models was constructed by sampling all the main ionic current conductances, namely, INa, INaL, ICaL, ICaT, Ito, Isus, IKr, IKs, If, IK1, INCX, INaK, in the range [50–200]% of their baseline value, using Latin hypercube sampling [30]. The initial population was then calibrated through a multi-step process, based on the criteria 1–3 used for the development of the Trovato2020 model and our human experimental Datasets II and III.

In the first calibration step, only the models with all AP biomarkers within the minimum and maximum experimental values at all BCLs (Table 1) were selected. To constrain the AP plateau within the experimental traces, two additional biomarkers at 1 Hz were considered, similar to [19]: the voltage level measured 25 and 50 ms after the AP upstroke. In the second calibration step we selected only the models showing APD90 rate-dependence in line with experiments. As third calibration step, we selected only the models showing a direct dependence of APD90 on ICaL.

Simulations in control conditions and with dofetilide were performed for all models in the calibrated population, and results were compared to the experimental Dataset III. Finally, EADs and DADs inducibility was also tested using the calibrated population, to investigate the mechanisms underlying EADs and DADs generation in human PCs. To do this, protocols 5 and 6 (Section 2.5) were simulated for each model in the calibrated population. EADs were identified when a positive derivative of the membrane potential was observed, from 150 ms after the stimulus [31]. DADs were identified as a deflection of the membrane potential larger than 1 mV during the diastolic phase. AP biomarkers, current conductances and model dynamics were analysed to identify the key mechanisms underlying EADs and DADs generation.

2.5. Stimulation protocols

Single cell model equations were implemented in Matlab (Mathworks Inc. Natwick, MA, USA) and solved with the function ode15s, an adaptive time step solver for stiff problems [32]. Data analysis was also performed using Matlab. Simulations for the population of models were run on the Oxford supercomputer ARCUS (http://www.arc.ox.ac.uk/). The monodomain formulation was used to simulate propagation along the fibre [33] and was solved using the Fourier spectral method for fractional diffusion [34]. The Rush-Larsen method was implemented for the integration to speed up the simulations [35] in Matlab.

The calibration and validation criteria described in Section 2.2 were evaluated using 9 different simulation protocols, 6 for calibration, 2 for validation and 1 for comparison against voltage-clamp experiments. A list of the protocols is provided below:

  • 1)

    Control conditions. Steady state (SS): 1000 beats at 1 Hz, to allow the intracellular concentrations to reach stability.

  • 2)

    Rate dependence. Starting from SS, 150 beats for each BCL, from 300 ms to 5000 ms.

  • 3)

    ICaL modulation. Starting from SS, 150 beats at 1 Hz with up/down regulation of the ICaL conductance (±30%).

  • 4)

    IKr block. Starting from SS, 150 beats at 1 Hz with IKr block (at 30% and 50%).

  • 5)

    EADs inducibility. Starting from SS, 150 beats at slow pacing (BCL = 4000 ms) with 85% IKr block, as in [21].

  • 6)

    DADs inducibility. Starting from SS, 1500 beats at fast pacing (BCL = 300 ms, 3.3 Hz), with and without RyR hypersensitivity. The model was then left unstimulated for 10s to allow for any potential DADs or triggered APs to arise. RyR hypersensitivity was simulated as an increased sensitivity to intracellular Ca2+ (+100%) and a decrease in the release time constant (−70%), similar to [14].

  • 7)

    Dofetilide. Starting from SS, 150 beats at 1 Hz and 2 Hz, using a simple pore-block drug model [36] with IC50 (in μM) and Hill coefficient (IC50/h) for IKr, INa and ICaL equal to 0.03/1.2, 162.1/1 and 26.7/1, respectively [37].

  • 8)

    Automaticity. Starting from SS, 3 different combinations of If and IK1 were tested: i) 90% IK1 block; ii) increasing If 9-folds; iii) combining the 2 conditions, 50% IK1 block and 4-folds If. The values of IK1 and If conductances were identified through a sensitivity analysis up to automaticity appearance. The model was stimulated for 150 beats at 1 Hz, followed by 15 s with no stimulation. The same simulations were repeated under hyperkalaemia with extracellular [K+] set to 8 mM to reproduce the same conditions as in [8].

  • 9)

    Voltage clamp simulations (for I-V curves). 1000 ms at holding voltage (−40 for IK1 and − 50 mV for both Ito and Isus) followed by a step (300 ms for Ito and 100 ms for both IK1 and Isus) at different voltage values (from −120 mV to 0 mV for IK1, and from −50 mV to +60 mV for both Ito and Isus). Intracellular [Na+], [Ca2+] and [K+] were set to 0.0001 mM, 0.0001 mM and 130 mM, respectively, while their corresponding extracellular concentrations were 140 mM, 1 mM, 5.4 mM, respectively, as in the experiments by Han et al. [9].

3. Results

3.1. Simulations with the optimised Trovato2020 model reproduce experimental AP recordings and fulfil all calibration criteria

Optimisation using the genetic algorithm produced a Pareto optimal front of 105 models, including many duplicates of 8 unique models. The final optimised Trovato2020 model was identified as the model with the best performance across all the tested protocols. Parameters and simulation results for the 8 models are shown in Fig. S4. Table 2 reports the simulated AP biomarkers for the optimised Trovato2020 vs the non-optimised model, and the human experimental biomarker ranges from Dataset II at 1 Hz.

Table 2.

Simulated and experimental AP biomarkers.

Experiments Initial model Optimised model
dV/dtMax (V/s) 387 ± 143 435 381
APD90 (ms) 294 ± 76 249 306
APD75 (ms) 261 ± 67 225 279
APD50 (ms) 210 ± 52 168 223
APD25 (ms) 117 ± 46 116 142
APD10 (ms) 33 ± 35 49 34
APA (mV) 106 ± 7 113 110
TOP (mV) −85 ± 2.4 −86.7 −86.5
EOP (mV) −86 ± 2 −87.2 −87.3

Comparison between experimental and simulated AP biomarkers using the initial and optimised models at 1 Hz (mean ± std).

dV/dtMAX: maximum upstroke velocity; APDx: AP duration at X% of repolarisation; APA: action potential amplitude; TOP: membrane potential before depolarisation; EOP: membrane potential at the end of repolarisation.

Fig. 2 shows the simulation results for the optimised Trovato2020 model, reproducing Datasets I and II and satisfying each of the 6 calibration criteria: simulations of voltage-clamp protocols for Ito, Isus and IK1 to reproduce the experimental I–V curves from Dataset I (Panel A); AP traces at 1 Hz and rate dependence in line with experimental recordings from Dataset II (Panel B and C, respectively); APD90 changes induced by ICaL modulation (Panel D) and IKr block (Panel E); EADs and DADs inducibility (Panel F and G, respectively). Further information on the ionic currents underlying the AP and Ca2+-transient in the optimised model at 1 Hz are included in the Supplementary Material, Fig. S5.

Fig. 2.

Fig. 2

Simulations results obtained with the optimised Trovato2020 model (black), compared against the corresponding experimental data (green), when available: A) I-V curves for IK1 (left), Ito (middle) and Isus (right). Experimental data from Dataset I [9]. B) AP traces at 1 Hz. Experimental data from Dataset II. C) APD90 rate-dependence. Experimental data from Dataset II. D) AP changes induced by ICaL conductance modulation. E) AP changes induced by IKr block. F) EADs observed at slow pacing with IKr block. G) DADs following fast pacing with RyR hypersensitivity. No DADs were observed in control. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

As expected, fast Na+ current activation drives the depolarisation phase with dV/dtMAX = 381 mV/s, 24 mV voltage peak and 110 mV amplitude (Table 2). During the early-repolarisation phase, simulated AP (Fig. 2B) presents a “spike and dome” waveform (Fig. 2B inset), due to the interplay between the depolarising currents ICaL and INaL and the repolarising Ito and Isus. The repolarisation phase is driven by IKr, IKs and IK1, resulting in APD90 of 306 ms at 1 Hz. The small diastolic depolarisation (~1 mV), due to the action of If, is in agreement with the difference observed experimentally between potentials at take-off and end of repolarization (EOP vs TOP). No automaticity was observed, in agreement with experimental recordings from Dataset II and the literature [7]. The correlation coefficients between AP biomarkers and ionic current conductance at 1 Hz are reported in Table S2.

Rate-dependence of APD90 is in line with experimental recordings from Dataset II (Fig. 2C). At BCL = 400 ms, the APD90 is 250 ms and increases up to 312 ms at BCL = 5000 ms. Furthermore, the optimised model reproduces a positive correlation between APD and ICaL modulation (Fig. 2D): small changes in ICaL conductance affect the plateau phase, with small changes in APD90 as reported for rabbit PCs [38]. However, a stronger ICaL block also causes APD90 shortening, as in experimental recordings using canine PCs [[22], [23]].

Simulations with the new human Purkinje Trovato2020 model yield APD prolongation following IKr block (Fig. 2E): 30% and 50% IKr blocks prolong APD90 from 306 (control) to 365 and 421 ms, respectively, whereas the same degrees of block in the human ventricular ORd model prolong the APD90 from 269 ms (control) to 329 and 386 ms, respectively. These results are in agreement with canine experiments [24] showing a longer AP in Purkinje compared to ventricular myocytes, both in control conditions and following IKr block.

EADs inducibility is shown in Fig. 2F: at BCL = 4000 ms, the AP fully repolarises in control (APD90 = 307 ms, dashed line), whereas an EAD occurs with 85% IKr block (solid line).

DADs inducibility is illustrated in Fig. 2G: following fast pacing, the Trovato2020 model remains well polarised in control conditions (dashed line), while DADs occur when including RyR hypersensitivity (solid line). The initial DADs amplitude is 6 mV, and it decreases to less than 1 mV after 13 s. Even after 300 s, the model exhibits oscillations albeit of amplitude smaller than 0.01 mV, and therefore potentially undetectable experimentally. The ionic mechanisms of EADs and DADs generation are investigated in Section 3.6 and 3.7.

Further analysis of the optimised Trovato2020 model is included in the Supplementary Material, including the sensitivity analysis (Section 4, Fig. SA1–SA5).

3.2. Model validation: response to dofetilide and automaticity

Fig. 3A illustrates the agreement of simulation results with experiments from Dataset III, in control conditions (blue) and with dofetilide (red), at 1 and 2 Hz (left and right, respectively).

Fig. 3.

Fig. 3

Independent validation of the optimised Trovato2020. A) Comparison between the human experimental AP traces from Dataset III (top panels, n = 3) and the simulations with the Trovato2020 model (bottom panels), in control conditions (blue) and with Dofetilide 100 nM (red), at 1 Hz (left) and 2 Hz (right). B) Ability of the model to develop automaticity when no external stimulus (blue asterisks) is applied. Simulations are shown both with normal [K+]o (black) and under hyperkalaemia conditions (light blue), in four different scenarios. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Fig. 3B illustrates the ability of the Trovato2020 model to display automaticity following IK1 decrease and/or If increase. When including either IK1 down-regulation, If up-regulation, or a combination of both, the DMP increases much faster during the resting phase, and automaticity is observed at BCL of 2.5, 1.6 and 1.9 s, respectively. These results are in line with the BCL range of 1.3–3.0 s experimentally observed by [8,15], and also with [2,39], reporting that PCs with less negative DMP show automaticity, while well polarised PCs remain quiescent. Hyperkalaemia stops the automaticity in the two scenarios including If up-regulation, in agreement with experiments in human PCs [8], whereas it increases the spontaneous firing rate when automaticity is induced only by IK1 down-regulation.

3.3. Comparison with previous cardiac Purkinje in silico models

The Trovato2020 model was compared with two other human Purkinje models available in the literature (TT08 and STW). Fig. S6A depicts the simulated APs at 1 Hz for the three models with experimental APs from Dataset II, while the corresponding AP biomarkers are reported in Table S3. Simulation results obtained with both TT08 and STW overestimate the rate of depolarisation (742 and 522 V/s, respectively), compared to experiments from Datasets II and III, and the literature, i.e., 388 ± 25 V/s [40] and 207 ± 26 V/s [8].

Trovato2020 and TT08 have similar DMP, whereas STW is significantly less negative. Indeed, STW shows automaticity in control conditions, while Trovato2020 reproduces the quiescent PCs in control, and automaticity with less negative DMP. TT08 does not include any formulation for the If, and it does not yield automaticity under the protocols considered in this study (Section 2.5).

Both Trovato2020 and TT08 show an APD rate dependence in line with the experiments (Fig. S6B), even if TT08 largely overestimates the APD90 at all BCL, while STW shows a non-physiological rate dependence. Simulations with TT08 and STW failed to reproduce EADs with protocol 5 (Fig. S6C), only showing AP prolongation (17% and 42%, respectively). Both TT08 and STW also underestimate the AP prolongation induced by dofetilide (Fig. S6D), compared to our Dataset III. Finally, neither TT08 nor STW are capable of developing DADs at fast pacing, even when considering RyR hypersensitivity. Therefore, the novel Trovato2020 model is more suitable than both TT08 and STW for mechanistic investigations of arrhythmias considering EADs, DADs, triggered activity as well as APD rate dependence.

The Trovato2020 model was also compared with the ORd and PRd models: simulated AP biomarkers are reported in Table S3, whereas, APs, intracellular Ca2+ concentrations and the three refitted K+ currents, Ito, Isus, IK1, at 1 Hz are reported in Fig. S6E. The simulated AP with the Trovato2020 model displays a smaller peak potential than both ORd and PRd, faster upstroke velocity than ORd but slower than PRd, AP plateau similar to PRd and lower than ORd, and finally, APD90 longer than ORd but shorter than PRd. Intracellular [Ca2+] is smaller with the Trovato2020 model than with ORd, but similar to the one with PRd, which was based on experimental data from canine PCs [41]. In particular, Trovato2020 and PRd have the same level of diastolic [Ca2+] and same delay in the Ca elevation time (~100 ms). Similarly, the [Ca2+] of the sub membrane compartment obtained with the Trovato2020 was similar to the one simulated with PRd, whereas the ORd does not implement such compartment.

The refitted K+ currents Ito, Isus and IK1 were compared as well (Fig. S6E). The simulated Ito with Trovato2020 is bigger than with ORd but smaller than PRd, as suggested by experiments in human and canine PCs [[9], [42]]. In all three models, its contribution ends after 20 ms. Isus, not implemented in ORd, displays lower amplitude in Trovato2020 than in PRd, similarly to Ito. Simulated IK1 with Trovato2020 is smaller than both ORd and PRd, in line with the reduced level of expression of IK1 proteins in human Purkinje [43,44].

Trovato2020, ORd and PRd share the same model for CaMKII signalling [45]. Similarly to the ORd, removing CaMKII from the Trovato2020 model (Fig. S7A) reduces intracellular and submembrane [Ca2+] peak, with minimum changes on the APD and [Ca2+] rate-dependence. The decreased [Ca2+] due to CaMKII signalling removal had no effects on DADs induced at fast pacing with RyR hypersensitivity (Fig. S7B), though also the sarcoplasmic [Ca2+] was reduced. No effects were observed on EADs dynamics, as expected due to the low pacing frequency.

3.4. A population of human Purkinje Trovato2020 models accounting for biological variability

The optimised human Trovato2020 model was used as baseline to construct a population of models, to capture the biological variability in the AP morphology observed in the experimental Dataset II. The initial population (n = 3000) was calibrated through a multi-step filtering process, as described in Methods, and summarised in Fig. 4.

Fig. 4.

Fig. 4

Simulation results for the population of Trovato2020 models, including calibration (A-C), validation (D), and investigation of EAD and DAD inducibility (E-F). A) Results of the first calibration step, based on AP biomarkers. AP traces are shown for the baseline model (red), the discarded models (grey), and the accepted models (blue), compared against experimental traces from Dataset II (green). B) Results of the second calibration step, based on APD90 rate-dependence. C) Results of the third calibration step, based on ICaL modulation of APD90. D) Comparison of APs with the experimentally-calibrated population of Trovato2020 models against experimental data from Dataset III. Boxplots represent the APD90 distribution at 1 Hz (left) and 2 Hz (right) in control conditions (blue) and with Dofetilide 100 nM (pink). Simulation results with the baseline model are reported as a red star, while experimental data are shown as green squares. On each box, the central mark is the median of the population, box limits are the 25th and 75th percentiles, and whiskers extend to the most extreme data points not considered outliers, plotted individually as separate crosses. E) Top panel: Simulated AP traces for the EADs protocol, including the baseline model (black), models not displaying EADs (blue), and models displaying EADs (pink). The baseline model is shown in black. Bottom panel: Distribution of the scaling factors of the ionic current conductances varied in the population of models, highlighting the differences between the two groups of models. F) Top panel: Simulated AP traces for the DADs protocol, including the baseline model (black), models not displaying DADs (blue), models displaying DADs (pink), and models displaying triggered APs (green). Bottom panel: distribution of the scaling factors of the ionic current conductances varied in the population, highlighting the differences between the three groups of models. Boxplot description as in D. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

In the first calibration step, only the models in agreement with the experimental biomarkers at all BCLs were selected (n = 1025), while the others were discarded (n = 1975). Fig. 4A reports the simulated APs for the baseline Trovato2020 model, the initial population and the experimental traces at 1 Hz. In the second calibration step, n = 867 models showed APD90 rate dependence in line with the experiments and were kept in the population (Fig. 4B). In the last calibration step, n = 497 models were accepted into the final population, all displaying a positive correlation between APD and ICaL (Fig. 4C). These models were used for all subsequent investigations.

Fig. 4D illustrates the APD distribution in the population, both in control conditions (blue) and with dofetilide (pink), at 1 Hz and 2 Hz (left and right, respectively), compared against the experimental APD values from Dataset III. Simulation results for the population are in agreement with the experimental values in control conditions and with dofetilide at 1 Hz. The simulated APs with the population yield a wider range of APD prolongation compared to experiments, similar to what was previously shown for rabbit PCs [19].

3.5. EADs mechanisms

When simulating the EADs protocol (described in Section 2.5) in the experimentally-calibrated population of models (Fig. 4E, top panel), 59% of the models (n = 296) developed EADs (pink traces), while the rest of the models only displayed AP prolongation (blue traces). Multiple EAD phenotypes were observed, in agreement with previous experimental and simulation studies [31,46,47]. The distribution of the ionic current conductances (Fig. 4E, bottom panel) highlights the differences between these two groups of models. Models displaying EADs were mainly characterised by larger inward current conductances (GCaL and GNaL), in agreement with the sensitivity analysis results (Supplemental Material, Section 4, Figure SA4). ICaL re-activation (Fig. 5A) was identified as the key mechanism for EAD generation [48,49] whereas, no INaL reactivation was observed with the protocol used in this study [50]. Fig. 5B reports intracellular and sub membrane [Ca2+] peak values in control using the models displaying only AP prolongation and those developing EADs.

Fig. 5.

Fig. 5

EADs and DADs mechanisms. A) Simulations of the EADs protocol, showing the AP and the main currents/concentrations involved in EADs generation. 6 representative models are shown: 3 not displaying EADs (left), and 3 displaying EADs (right). All models exhibiting EADs display ICaL re-activation, as shown by ICaL activation gate dynamics (4th row from top). B) Intracellular and sub membrane [Ca2+] peaks (computed before IKr block) for models showing only AP prolongation (blue) and those developing (EADs). C) Simulated APs and main currents/concentrations involved in DADs generation. 17 representative models are shown: 10 not displaying DADs (blue), 5 displaying DADs (pink), and 2 developing triggered APs (green). All models displaying DADs or triggered APs have higher [Ca2+]i, [Ca2+]sl and [Ca2+]NSR. D) Intracellular and sub membrane [Ca2+] amplitude, and mean sarcoplasmic [Ca2+] for all the models in the calibrated population: not displaying DADs (blue), displaying DADs (pink) and developing triggered APs (green). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

3.6. DADs mechanisms

When simulating the DADs protocol (described in Section 2.5) in the experimentally-calibrated population (Fig. 4F, top panel), 63 models developed DADs (pink traces), 5 models developed triggered APs (green traces), while no DADs were observed in the remaining models (blue traces). The distribution of the ionic current conductances (Fig. 4F, bottom panel) highlighted the differences between these three groups of Purkinje models. Human virtual PCs displaying DADs had larger GCaL, and reduced GNCX.

Fig. 5C illustrates the ionic mechanisms underlying DADs formation. Models displaying DADs showed higher Ca2+ concentrations in all intracellular compartments, including the SR. In particular, in all models displaying DADs, [Ca2+]NSR was larger than 1.7 mM, in line with previous computational studies [[51], [52], [53]] and also larger than in the baseline model with RyR hypersensitivity (1.1 mM, Fig. S7B). Ca2+ accumulation made the cell more vulnerable to spontaneous SR Ca2+ release, which were translated by the INCX into the depolarising currents causing DADs. Fig. 5D shows intracellular and submembrane [Ca2+] amplitudes, i.e., the difference between the diastolic concentration and the peak value for each cellular compartment, and the average sarcoplasmic [Ca2+] of the models staying quiescent and those developing DADs and triggered APs across the whole calibrated population.

In order to establish the link between the distribution of ionic current conductances and Ca2+ accumulation in the models displaying DADs, we performed additional ad hoc simulations for a selection of 3 models from the population. We selectively restored ionic current conductances to their baseline values, and evaluated changes in Ca2+ accumulation and DADs generation. Large GCaL and small GNCX directly contributed to Ca2+ overload and DADs generation: restoring the value of either of these conductances to their baseline significantly reduced intracellular Ca2+ concentrations, and also abolished DADs (Fig. S8, Panel A and B).

Triggered APs were observed in ~1% of the experimentally-calibrated population (n = 5 models). All models developing triggered APs were characterised by smaller GK1 and GNaK (Fig. 4F), both reducing the outward current during the diastolic phase, and had higher intracellular Ca2+ concentrations, compared to the ones developing DADs only (Figure 5B).

3.7. Simulation results in a human Purkinje 1D fibre

Fig. 6 summarises the simulations results for the human Purkinje 1D fibre considering the optimised Trovato2020 model in control conditions (Fig. 6A) and one of the model variants displaying automaticity in single cell as reported in Section 3.2 (Fig. 6B). Spontaneous APs propagated along the whole fibre, with no changes in the BCL compared to single cell simulations. Fig. 6C shows the results with the optimised Trovato2020 model and the EADs protocol: EADs were observed in the whole fibre, with no changes in EADs amplitude induced by the intercellular coupling. Fig. 6D shows the results of one of the models in the population developing both triggered APs and DADs at fast pacing (Fig. 5C): in this case, the electrical coupling affected the simulations since only a single triggered APs was observed in fibre, compared to the 2 observed in the single cell simulations. After the fast pacing, the fibre depolarised generating one DAD (t = 550 ms, Fig. 6D) but it did not reach the threshold to allow fast Na+ channels opening. Though, after another further 650 ms the membrane reached the threshold and a spontaneous AP was elicited, followed by 2 DADs, as in the single cell simulations. However, when the electrophysiological changes underlying EADs and DADs were applied only to the central portion of the fibre (1.67 cm, 33 nodes), abnormalities did not propagate due to the sink-source mismatch as previously reported by Xie et al. [54].

Fig. 6.

Fig. 6

Simulation results for a 1D human cardiac Purkinje fibre constructed using the Trovato2020 model. A) Simulated AP in control conditions, propagating along the fibre. The delay between the AP upstroke at the proximal and distal ends is 32 ms. B) Simulation results obtained with one of the variants of the Trovato2020 model displaying automaticity (increased If, reduced IK1). Spontaneous APs were observed in the fibre, and the CL was not different than the one obtained in single cell simulations. C) Simulation results for the EADs inducibility protocol. EADs propagated along the fibre. D) Simulation results for the DADs inducibility protocol, using one of the models in the population displaying triggered APs. The cellular coupling reduced the number of triggered APs compared to single cell simulations (from 2 to 1). All the panels share the same colour map, displayed on the right. Please note the different time scales (ms for A and C, s for B and D). Arrows indicate time and sites of pacing.

INa block caused reduction in CV (Table S4): for INa blocks of 30%, 50% and 90%, CV decreased by 8%, 15% and 45%, respectively, compared to the control value of 160 cm/s. Even with 95% INa block, the AP was still able to propagate, even though CV was reduced to 69 cm/s (−57%). AP failed to propagate only with a complete block of INa.

4. Discussion

4.1. The novel human Purkinje AP model

In this study, the novel human PC Trovato2020 model was presented, including its construction, calibration, optimisation and independent evaluation using experimental AP recordings from undiseased human PCs and knowledge about Purkinje-specific currents and Ca2+-handling. Parameter optimisation was performed using a multi-objective genetic algorithm and sensitivity analysis, to overcome manual tuning limitations. Independent model validation was conducted using AP recordings from undiseased human PCs in control and with dofetilide, and also based on the model's ability to reproduce EADs, DADs and trigger activity using specific protocols. Both single cell and 1D fibre simulations were performed using a variety of stimulation protocols. In addition, an experimentally-calibrated population of human PC models was also constructed to account for biological variability, and used to investigate the ionic mechanisms underlying EADs and DADs generation in human PCs. The main findings of this study are:

  • 1.

    Simulation results with the Trovato2020 model are in agreement with the key features of human Purkinje APs reported in the human experimental datasets presented in this study and from the literature. Simulations reproduce a wide range of stimulation protocols, including different pacing frequencies and selective channel blocks.

  • 2.

    The Trovato2020 model is able to yield and explain pro-arrhythmic mechanisms, i.e. EADs and DADs, in human PCs. Simulations show that 59% of the PCs models in the population display EADs caused by ICaL reactivation and favoured by strong ICaL and INaL. DADs are observed in 13% of the Purkinje population models, displaying Ca2+ accumulation both in the intracellular space and into the sarcoplasmic reticulum. Triggered APs were observed in 1% of the virtual PCs, which displayed strong downregulation of IK1 and INaK.

  • 3.

    Integration of the Trovato2020 model in a 1D fibre succeed to reproduce AP propagation, automaticity, EADs, DADs and triggered APs in tissue. It can be implemented in higher scale models for investigation also at tissue and organ level.

The Trovato2020 Purkinje model integrates and expands a large amount of knowledge and experimental data obtained from human Purkinje preparations. It is the first human Purkinje model incorporating a Ca2+ handling with the 3 SR compartments and 3 different types of Ca2+ releases, based on the Purkinje-specific structure [55] already implemented for rabbit [19] and canine [14] models. Previously published human Purkinje models [[15], [16], [17]] include only 2 intracellular compartments and 1 type of Ca2+ release, inherited from ventricular models. Thus, they do not account for Purkinje specific features such as the low density of t-tubuli and different type of Ca2+ releases. A physiological Purkinje Ca2+-handling representation is crucial, since it can favour arrhythmogenesis in pathology [1] and upon pharmacology interventions [13]. The Purkinje-specific Ca2+ handling model introduces a delay in the Ca2+ diffusion from the sub-membrane to the cellular bulk, and therefore, an intracellular [Ca2+] gradient (Fig. S5). The simulated [Ca2+]i of the new Purkinje model in control conditions is smaller and delayed compared to the [Ca2+] in the sub-membrane space as reported by [[55], [56], [57]]. The smaller Ca2+ transient is correlated with scarce myofibrils, according to the lower contractile ability of Purkinje compared to ventricular cardiomyocytes [13].

Simulations with the human Purkinje Trovato2020 model revealed that the balance between IK1 and If determines the DMP and, therefore also automaticity, as previously suggested experimentally by [2,58]. The simulation results are also in agreement with [8], in showing pacemaker activity in human PCs with elevated diastolic transmembrane potential (TOP ~ −70) in control condition. Hyperkalaemia stopped pacemaker activity, as also reported experimentally [8], but only when automaticity was due to If up-regulation, since high potassium concentration up-regulates IK1 making the resting more stable. This does not occur when automaticity was induced only by IK1 down-regulation, suggesting a more physiological role of If in setting PC automaticity compared to pure IK1 down-regulation’. Heterogeneity in the DMP and automaticity may lead to conduction block, creating the substrate for micro and/or macro re-entry, and eventually arrhythmia [1].

The human Purkinje Trovato2020 model was also able to reproduce the effects of potassium and calcium channel block on repolarization properties, as well as sodium channel block on electrical propagation. The simulation results were in agreement with human experimental data acquired at several frequencies, both in control conditions and following dofetilide application. Simulations with dofetilide at 2 Hz (Fig. 4D) showed reverse rate-dependence, i.e., less prolongation at higher frequencies, in agreement with observations both in human and animal preparations [59], while a larger APD prolongation is observed in the human recordings from Dataset III. These results lend credibility to the new model for in silico drug trials in human PCs to assess drug efficacy and/or drug-induced cardiotoxicity, as done using human ventricular models [60].

4.2. EADs and DADs mechanisms

Afterdepolarisations in Purkinje cardiomyocytes can act as triggers of ectopic activity and arrhythmia, particularly in diseased or drug action conditions [1]. The Trovato2020 model is the first human Purkinje model able to reproduce EADs, DADs and triggered AP in single cell and 1D fibre. This enables the investigation of PCs as arrhythmia triggers [61,62], in addition to their contribution to the substrate for re-entry circuits and retrograde propagation [63,64]. Therefore, the integration of the Trovato2020 model in tissue or whole-ventricular models, including the Purkinje tree [65,66], could enable investigations into the role of PCs in human ventricular arrhythmias, caused by relevant disease conditions such as myocardial infarction [[67], [68], [69], [70], [71]], ischemic heart disease [72,73], structural heart disease [74], CPVT [75], post-shock arrhythmia [64], Brugada and Long QT syndromes, both acquired or drug-induced [3,76,77].

In this study, pro-arrhythmic electrical abnormalities i.e. EADs, DADs and triggered APs were investigated at cellular and fibre scale also including biological variability through the population of models approach. Our simulations report that EADs, DADs and triggered APs are based on different ionic mechanisms, which are consistent with previous investigations in other species [2,14,78,79].

Across all the simulations, EADs were uniquely due to ICaL reactivation, and occurred in models with strong ICaL upregulation, and also with high INaL. This is consistent with simulation results using human ventricular models [31,60]. No INaL re-activation was observed during EADs, although this may occur using a different protocol [50]. Simulations in tissue confirmed that EADs are able to propagate along the whole fibre and demonstrated the possibility of using the model to investigate PCs as arrhythmia trigger in tissue and whole-organ simulations.

Moreover, across the population of models, DADs generation required Ca2+ accumulation both in the SR and in the intracellular space at fast pacing (Fig. 5B). DADs and triggered APs in PCs have been clinically related to arrhythmia initiation [1]. They are suspected to trigger postshock arrhythmias such as ventricular tachycardia and fibrillation after a successful defibrillation of the heart [52]. The mechanisms underlying DADs have been difficult to unravel, but many experimental and simulation studies identified the important role of Ca2+ dynamics [1]. In general, experiments across a wide range of protocols, suggested that the key feature for DADs generation is Ca2+ overload, though the mechanisms necessary for DADs are still being debated [53]. Our study suggests a similar mechanism also in human Purkinje cells, and identifies ICaL and INCX as the ionic currents playing a major role in DADs inducibility, and IK1 and INaK for triggered APs. The present study helps in the translation from animal to human studies, and provides a new and needed tool for in silico investigation of arrhythmia, including the Purkinje system and its electrophysiology.

4.3. Limitations

The Trovato2020 model presented in this study was built using the human ventricular ORd model, the Purkinje-specific Ca2+ sub-system, cellular compartments and intracellular ionic fluxes of the canine PRd model and experimental human data. The model was calibrated using the only currently available dataset from undiseased human PC and validated against an independent experimental dataset from human undiseased hearts in control and with dofetilide, not used for the model calibration and optimisation. The latter also represent the first published dataset from undiseased human PCs under drug action. We cannot exclude the possibility that connexin-mediated electrotonic interactions between PCs and ventricular tissue might have affected the AP waveforms of our experimental datasets, in particular, during the early repolarisation phase. A limitation of this study is the lack of experimental data on the Ca2+ transients in human cardiac PCs, since there are no recordings available. Data on human PCs AP response to pure ICaL modulations are also lacking. However, previous studies using animal Purkinje and human ventricular preparations suggest positive correlation between APD90 and ICaL modulation. Preparations used in Dataset I were obtained from failing hearts, which could affect Ito, Isus, IK1 measurements. This uncertainty was tackled in our study through a population of models investigation using hundreds of models. During the model development, we used the original ORd human ventricular current formulation of currents, whose data were no available for human PCs (e.g., IKs, INCX, INaK). This is further supported by the fact that there are no reports on different isoforms in human ventricular versus Purkinje cardiomyocytes. If and ICaT formulations were adopted from the canine PRd model. However, ICaT does not play an important role in PCs dynamics and abnormalities, and there are no reports of significant differences between canine and human If in PCs.

Author contributions

CT, EP, SS, BR conceived and designed the study; CT and EP designed the models. CT performed the simulations, analysed the data, prepared the figures and drafted the manuscript; NN and AV provided the experimental data for Dataset II; NAG provided the experimental data for Dataset III. CT, EP and BR interpreted the results; all the authors edited and revised the manuscript, and approved the final version.

Declaration of Competing Interest

CT, EP, NN, AV, SS and BR declare no conflicts of interest. NAG is an employee of AnaBios Corporation.

Acknowledgments

CT, EP and BR were respectively supported by a DPhil scholarship funded by the Department of Computer Science (University of Oxford), an NC3Rs Infrastructure for Impact Award (NC/P001076/1), and a Wellcome Trust Senior Research Fellowship in Basic Biomedical Sciences (100246/Z/12/Z, 214290/Z/18/Z). These authors also acknowledge additional support from EPSRC Impact Acceleration Awards (EP/K503769/1), the CompBioMed project (European Commission grant agreements No 675451 and 823712), the Oxford BHF Centre of Research Excellence (RE/08/004/23915, RE/13/1/30181), the PRACE project (2017174226), an Amazon Web Services Research Award and the TransQST project (Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116030, receiving support from the European Union's Horizon 2020 research and innovation programme and EFPIA). NN was supported by grants from the National Research Development and Innovation Office (NKFIH PD-125402, FK-129117), the János Bolyai Research Scholarship of the Hungarian Academy of Sciences. VA was supported by National Research Development and Innovation Office K-119992 and GINOP-2.3.2-15-2016-00047, the Ministry of Human Capacities Hungary (20391-3/2018/FEKUSTRAT and EFOP-3.6.2-16-2017-00006-LIVE LONGER) and by the Hungarian Academy of Sciences. The GINOP and EFOP projects are co-financed by the European Union and the European Regional Development Fund.The authors also want to thank Dr. Alfonso Bueno-Orovio, Dr. Jakub Tomek and Dr. Michelangelo Paci for their help and support during the development of the model.

Footnotes

Appendix A

Supplementary data to this article can be found online at https://doi.org/10.1016/j.yjmcc.2020.04.001.

Contributor Information

Cristian Trovato, Email: cristian.trovato@cs.ox.ac.uk.

Blanca Rodriguez, Email: blanca.rodriguez@cs.ox.ac.uk.

Appendix A. Supplementary data

Supplementary material

mmc1.pdf (4.6MB, pdf)

References

  • 1.Haissaguerre M., Vigmond E., Stuyvers B., Hocini M., Bernus O. Ventricular arrhythmias and the His–Purkinje system. Nat. Rev. Cardiol. 2016;13(3):1–12. doi: 10.1038/nrcardio.2015.193. [DOI] [PubMed] [Google Scholar]
  • 2.Dobrzynski H., Anderson R.H., Atkinson A., Borbas Z., Souza A.D., Fraser J.F. Pharmacology & Therapeutics Structure, function and clinical relevance of the cardiac conduction system, including the atrioventricular ring and out fl ow tract tissues. Pharmacol. Ther. 2013;139(2):260–288. doi: 10.1016/j.pharmthera.2013.04.010. [DOI] [PubMed] [Google Scholar]
  • 3.Iyer V., Roman-Campos D., Sampson K.J., Kang G., Fishman G.I., Kass R.S. Purkinje cells as sources of arrhythmias in long QT syndrome type 3. Sci. Rep. 2015;5:13287. doi: 10.1038/srep13287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Guth B.D. Preclinical cardiovascular risk assessment in modern drug development. Toxicol. Sci. 2007;97(1):4–20. doi: 10.1093/toxsci/kfm026. [DOI] [PubMed] [Google Scholar]
  • 5.Di Maio A., Ter Keurs H.E., Franzini-Armstrong C. T-tubule profiles in Purkinje fibres of mammalian myocardium. J. Muscle Res. Cell Motil. 2007;28(2–3):115–121. doi: 10.1007/s10974-007-9109-6. [DOI] [PubMed] [Google Scholar]
  • 6.Stuyvers B.D., Dun W., Matkovich S., Sorrentino V., Boyden P.A., Ter Keurs H.E.D.J. Ca2+ sparks and waves in canine Purkinje cells: a triple layered system of Ca2+ activation. Circ. Res. 2005;97(1):35–43. doi: 10.1161/01.RES.0000173375.26489.fe. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Boyden P.A., Hirose M., Dun W. Cardiac Purkinje cells. Heart Rhythm. 2010;7(1):127–135. doi: 10.1016/j.hrthm.2009.09.017. [DOI] [PubMed] [Google Scholar]
  • 8.Lee F.Y., Wei J., Wang J.J., Liu H.W., Shih T.C., Lin C.I. Electromechanical properties of Purkinje fiber strands isolated from human ventricular endocardium. J. Heart Lung Transplant. 2004;23(6):737–744. doi: 10.1016/s1053-2498(03)00230-4. [DOI] [PubMed] [Google Scholar]
  • 9.Han W., Zhang L., Schram G., Nattel S. Properties of potassium currents in Purkinje cells of failing human hearts. Am. J. Physiol. Heart Circ. Physiol. 2002;283(6 52-6) doi: 10.1152/ajpheart.00389.2002. (H2495–503) [DOI] [PubMed] [Google Scholar]
  • 10.Ono N., Yamaguchi T., Ishikawa H., Arakawa M., Takahashi N., Saikawa T. Morphological varieties of the Purkinje fiber network in mammalian hearts, as revealed by light and electron microscopy. Arch. Histol. Cytol. 2009;72(3):139–149. doi: 10.1679/aohc.72.139. [DOI] [PubMed] [Google Scholar]
  • 11.Lu H.R., Marien R., Saels A., Clerck F. Species plays an important role in drug-induced prolongation of action potential duration and early afterdepolarizations in isolated Purkinje fibers. J. Cardiovasc. Electrophysiol. 2001;12(1):93–102. doi: 10.1046/j.1540-8167.2001.00093.x. [DOI] [PubMed] [Google Scholar]
  • 12.Verkerk A.O., Veldkamp M.W., Abbate F., Antoons G., Bouman L.N., Ravesloot J.H. Two types of action potential configuration in single cardiac Purkinje cells of sheep. Am. J. Physiol. Circ. Physiol. 1999;277(4):H1299–H1310. doi: 10.1152/ajpheart.1999.277.4.H1299. [DOI] [PubMed] [Google Scholar]
  • 13.Nagy N., Szél T., Jost N., Tóth A., Gy Papp J., Varró A. Novel experimental results in human cardiac electrophysiology: measurement of the Purkinje fibre action potential from the undiseased human heart. Can. J. Physiol. Pharmacol. 2015;810(May):1–8. doi: 10.1139/cjpp-2014-0532. [DOI] [PubMed] [Google Scholar]
  • 14.Li P., Rudy Y. A model of canine Purkinje cell electrophysiology and Ca 2+ cycling. Circ. Res. 2011;109(1):71–79. doi: 10.1161/CIRCRESAHA.111.246512. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Stewart P., Aslanidi O.V., Noble D., Noble P.J., Boyett M.R., Zhang H. Mathematical models of the electrical action potential of Purkinje fibre cells. Philos. Trans. R. Soc. A Math. Phys. Eng. Sci. 2009;367(1896):2225–2255. doi: 10.1098/rsta.2008.0283. [DOI] [PubMed] [Google Scholar]
  • 16.ten Tusscher K.H.W.J., Panfilov A.V. Modelling of the ventricular conduction system. Prog. Biophys. Mol. Biol. 2008;96(1–3):152–170. doi: 10.1016/j.pbiomolbio.2007.07.026. [DOI] [PubMed] [Google Scholar]
  • 17.Sampson K.J., Iyer V., Marks A.R., Kass R.S. A computational model of Purkinje fibre single cell electrophysiology: implications for the long QT syndrome. J. Physiol. 2010;588(14):2643–2655. doi: 10.1113/jphysiol.2010.187328. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Muszkiewicz A., Britton O.J., Gemmell P.M., Passini E., Sánchez C., Zhou X. Variability in cardiac electrophysiology: using experimentally-calibrated populations of models to move beyond the single virtual physiological human paradigm. Prog. Biophys. Mol. Biol. 2015:1–13. doi: 10.1016/j.pbiomolbio.2015.12.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Britton O.J., Bueno-Orovio A., Van Ammel K., Lu H.R., Towart R., Gallacher D.J. Experimentally calibrated population of models predicts and explains intersubject variability in cardiac cellular electrophysiology. Proc. Natl. Acad. Sci. 2013;110(23):E2098–E2105. doi: 10.1073/pnas.1304382110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Page G., Ratchada P., Miron Y., Steiner G., Ghetti A., Miller P.E. Human ex-vivo action potential model for pro-arrhythmia risk assessment. J. Pharmacol. Toxicol. Methods. 2016;81:183–195. doi: 10.1016/j.vascn.2016.05.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.O'Hara T, Virág L, Varró A, Rudy Y. Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation. McCulloch AD, editor. PLoS Comput Biol 2011; 7(5): e1002061. [DOI] [PMC free article] [PubMed]
  • 22.Nánási P.P., Knilans T.K., Varró A., Murphy A.M., Fujiki A., Schwartz A. Active and passive electrical properties of isolated canine cardiac Purkinje fibers under conditions simulating Ischaemia: effect of diltiazem. Pharmacol. Toxicol. 1992;71(1):52–56. doi: 10.1111/j.1600-0773.1992.tb00520.x. [DOI] [PubMed] [Google Scholar]
  • 23.Terrar D.A., Wilson C.M., Graham S.G., Bryant S.M., Heath B.M. Comparison of Guinea-pig ventricular myocytes and dog Purkinje fibres for in vitro assessment of drug-induced delayed repolarization. J. Pharmacol. Toxicol. Methods. 2007;56(2):171–185. doi: 10.1016/j.vascn.2007.04.005. [DOI] [PubMed] [Google Scholar]
  • 24.Varro A., Baláti B., Iost N., Takács J., Virág L., Lathrop D.A. The role of the delayed rectifier component IKs in dog ventricular muscle and Purkinje fibre repolarization. J. Physiol. 2000;523(Pt 1):67–81. doi: 10.1111/j.1469-7793.2000.00067.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Roden D.M., Hoffman B.F. Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers. Relationship to potassium and cycle length. Circ. Res. 1985;56(6):857–867. doi: 10.1161/01.res.56.6.857. [DOI] [PubMed] [Google Scholar]
  • 26.Nattel S., Quantz M.A. Pharmacological response of quinidine induced early afterdepolarisations in canine cardiac purkinje fibres: insights into underlying ionic mechanisms. Cardiovasc. Res. 1988;22(11):808–817. doi: 10.1093/cvr/22.11.808. [DOI] [PubMed] [Google Scholar]
  • 27.Kang G., Giovannone S.F., Liu N., Liu F., Zhang J., Priori S.G. 2010. Purkinje Cells From RyR2 Mutant Mice Are Highly Arrhythmogenic But Responsive to Targeted Therapy; pp. 512–519. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Xing D., Martins J.B. Vol. 52242. 2019. Triggered Activity Due to Delayed After Depolarizations in Sites of Focal Origin of Ischemic Ventricular Tachycardia; pp. 2078–2084. [Google Scholar]
  • 29.Deb K. 2001. Multi-Objective Optimization Using Evolutionary Algorithms: An Introduction Multi-Objective Optimization Using Evolutionary Algorithms: An Introduction [Internet] pp. 1–24. Wiley-Interscience Series in Systems and Optimization. New York, NY, USA. [Google Scholar]
  • 30.McKay M.D., Beckman R.J., Conover W.J. A comparison of three methods for selecting values of input variables in the analysis of output from a computer code. Technometrics. 1979;21(2):239. [Google Scholar]
  • 31.Passini E., Mincholé A., Coppini R., Cerbai E., Rodriguez B., Severi S. Mechanisms of pro-arrhythmic abnormalities in ventricular repolarisation and anti-arrhythmic therapies in human hypertrophic cardiomyopathy. J. Mol. Cell. Cardiol. 2016;96(September):72–81. doi: 10.1016/j.yjmcc.2015.09.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Shampine L.F., Reichelt M.W. The MATLAB ODE suite. SIAM J. Sci. Comput. 1997;18(1):1–22. [Google Scholar]
  • 33.Keener J., Sneyd J. In: Mathematical Physiology. 2nd ed. Keener J., Sneyd J., editors. Springer New York; New York, NY: 2009. 2009 p. (Interdisciplinary Applied Mathematics; vol. 8/1) [Google Scholar]
  • 34.Bueno-Orovio A., Kay D., Burrage K. Fourier spectral methods for fractional-in-space reaction-diffusion equations. BIT Numer. Math. 2014;54(4):937–954. [Google Scholar]
  • 35.Rush S., Larsen H. A practical algorithm for solving dynamic membrane equations. IEEE Trans. Biomed. Eng. 1978;BME-25(4):389–392. doi: 10.1109/TBME.1978.326270. [DOI] [PubMed] [Google Scholar]
  • 36.Brennan T., Fink M., Rodriguez B. Multiscale modelling of drug-induced effects on cardiac electrophysiological activity. Eur. J. Pharm. Sci. 2009;36(1):62–77. doi: 10.1016/j.ejps.2008.09.013. [DOI] [PubMed] [Google Scholar]
  • 37.Kramer J., Obejero-paz C.A., Myatt G., Kuryshev Y.A., Bruening-Wright A., Verducci J.S. MICE models: superior to the HERG model in predicting torsade de pointes. Sci. Rep. 2013;3:2100. doi: 10.1038/srep02100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Lee H.-A., Hyun S.-A., Park S.-G., Kim K.-S., Kim S.J. Comparison of electrophysiological effects of calcium channel blockers on cardiac repolarization. Korean J. Physiol. Pharmacol. 2016;20(1):119–127. doi: 10.4196/kjpp.2016.20.1.119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Vassalle M. Analysis of cardiac pacemaker potential using a “voltage clamp” technique. Am. J. Physiol. Content. 1966;210(6):1335–1341. doi: 10.1152/ajplegacy.1966.210.6.1335. [DOI] [PubMed] [Google Scholar]
  • 40.Dangman K.H., Danilo P., Hordof A.J., Mary-Rabine L., Reder R.F., Rosen M.R. Electrophysiologic characteristics of human ventricular and Purkinje fibers. Circulation. 1982;65(2):362–368. doi: 10.1161/01.cir.65.2.362. [DOI] [PubMed] [Google Scholar]
  • 41.Boyden P.A., Pu J., Pinto J., Ter Keurs H.E.D.J. Ca 2+ transients and Ca 2+ waves in Purkinje cells. Circ. Res. 2000;86(4):448–455. doi: 10.1161/01.res.86.4.448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Han W., Chartier D., Li D., Nattel S. Ionic remodeling of cardiac Purkinje cells by congestive heart failure. Circulation. 2001;104(17):2095–2100. doi: 10.1161/hc4201.097134. [DOI] [PubMed] [Google Scholar]
  • 43.Gaborit N., Le Bouter S., Szuts V., Varró A., Escande D., Nattel S. Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart. J. Physiol. 2007;582(Pt 2):675–693. doi: 10.1113/jphysiol.2006.126714. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Jost N., Virág L., Comtois P., Ordög B., Szuts V., Seprényi G. Ionic mechanisms limiting cardiac repolarization reserve in humans compared to dogs. J. Physiol. 2013;591(Pt 17):4189–4206. doi: 10.1113/jphysiol.2013.261198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Decker K.F., Heijman J., Silva J.R., Hund T.J., Rudy Y. Properties and ionic mechanisms of action potential adaptation, restitution, and accommodation in canine epicardium. Am. J. Physiol. Heart Circ. Physiol. 2009;296(4):H1017–H1026. doi: 10.1152/ajpheart.01216.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Tran D.X., Sato D., Yochelis A., Weiss J.N., Garfinkel A., Qu Z. 258103(June) 2009. Bifurcation and Chaos in a Model of Cardiac Early Afterdepolarizations; pp. 1–4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Guo D., Liu Q., Liu T., Elliott G., Gingras M., Kowey P.R. Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J. Cardiovasc. Pharmacol. 2011;57(1):79–85. doi: 10.1097/FJC.0b013e3181ffe8b3. [DOI] [PubMed] [Google Scholar]
  • 48.Guo D., Zhao X., Wu Y., Liu T., Kowey P.R., Yan G.X. L-type calcium current reactivation contributes to arrhythmogenesis associated with action potential triangulation. J. Cardiovasc. Electrophysiol. 2007;18(2):196–203. doi: 10.1111/j.1540-8167.2006.00698.x. [DOI] [PubMed] [Google Scholar]
  • 49.Zeng J., Rudy Y. Early afterdepolarizations in cardiac myocytes: mechanism and rate dependence. Biophys. J. 1995;68(3):949–964. doi: 10.1016/S0006-3495(95)80271-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Morotti S., McCulloch A.D., Bers D.M., Edwards A.G., Grandi E. Atrial-selective targeting of arrhythmogenic phase-3 early afterdepolarizations in human myocytes. J. Mol. Cell. Cardiol. 2016;96:63–71. doi: 10.1016/j.yjmcc.2015.07.030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Luo C.H., Rudy Y. A dynamic model of the cardiac ventricular action potential. II. Afterdepolarizations, triggered activity, and potentiation. Circ. Res. 1994;74(6):1097–1113. doi: 10.1161/01.res.74.6.1097. [DOI] [PubMed] [Google Scholar]
  • 52.Maruyama M., Joung B., Tang L., Shinohara T., On Y.K., Han S. Diastolic intracellular calcium-membrane voltage coupling gain and postshock arrhythmias: role of purkinje fibers and triggered activity. Circ. Res. 2010;106(2):399–408. doi: 10.1161/CIRCRESAHA.109.211292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Fink M., Noble P.J., Noble D. Ca 2+ -induced delayed afterdepolarizations are triggered by dyadic subspace Ca 2+ affirming that increasing SERCA reduces aftercontractions. Am. J. Physiol. Circ. Physiol. 2011;301(3):H921–H935. doi: 10.1152/ajpheart.01055.2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Xie Y., Sato D., Garfinkel A., Qu Z., Weiss J.N. So little source, so much sink: requirements for afterdepolarizations to propagate in tissue. Biophys. J. 2010;99(5):1408–1415. doi: 10.1016/j.bpj.2010.06.042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Haq K.T., Daniels R.E., Miller L.S., Miura M., ter Keurs H.E.D.J., Bungay S.D. Evoked centripetal Ca 2+ mobilization in cardiac Purkinje cells: insight from a model of three Ca 2+ release regions. J. Physiol. 2013;591(17):4301–4319. doi: 10.1113/jphysiol.2013.253583. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.ter Keurs H.E.D.J., Boyden P.A. Calcium and Arrhythmogenesis. Physiol. Rev. 2007;87(2):457–506. doi: 10.1152/physrev.00011.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Cordeiro J.M., Spitzer K.W., Giles W.R., Ershler P.E., Cannell M.B., Bridge J.H.B. Location of the initiation site of calcium transients and sparks in rabbit heart Purkinje cells. J. Physiol. 2001;531(2):301–314. doi: 10.1111/j.1469-7793.2001.0301i.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Wiggins J.R., Cranefield P.F. Two levels of resting potential in canine cardiac Purkinje fibers exposed to sodium-free solutions. Circ. Res. 1976;39(4):466–474. doi: 10.1161/01.res.39.4.466. [DOI] [PubMed] [Google Scholar]
  • 59.Nánási P.P., Bárándi L., Virág L., Jost N., Horváth Z., Koncz I. Reverse rate-dependent changes are determined by baseline action potential duration in mammalian and human ventricular preparations. Basic Res. Cardiol. 2010;105(3):315–323. doi: 10.1007/s00395-009-0082-7. [DOI] [PubMed] [Google Scholar]
  • 60.Passini E., Britton O.J., Lu H.R., Rohrbacher J., Hermans A.N., Gallacher D.J. Human in silico drug trials demonstrate higher accuracy than animal models in predicting clinical pro-arrhythmic cardiotoxicity. Front. Physiol. 2017;8:1–15. doi: 10.3389/fphys.2017.00668. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Campos F.O., Shiferaw Y., Prassl A.J., Boyle P.M., Vigmond E.J., Plank G. Stochastic spontaneous calcium release events trigger premature ventricular complexes by overcoming electrotonic load. Cardiovasc. Res. 2015;107(1):175–183. doi: 10.1093/cvr/cvv149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Deo M., Boyle P.M., Kim A.M., Vigmond E.J. Arrhythmogenesis by single ectopic beats originating in the Purkinje system. Am. J. Physiol. Circ. Physiol. 2010;299(4):H1002–H1011. doi: 10.1152/ajpheart.01237.2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Akihiko N. Purkinje-related arrhythmias part I: monomorphic ventricular tachycardias. PACE - Pacing Clin. Electrophysiol. 2011;34(5):624–650. doi: 10.1111/j.1540-8159.2011.03044.x. [DOI] [PubMed] [Google Scholar]
  • 64.Boyle P.M., Deo M., Plank G., Vigmond E.J. Purkinje-mediated effects in the response of quiescent ventricles to defibrillation shocks. Ann. Biomed. Eng. 2010;38(2):456–468. doi: 10.1007/s10439-009-9829-4. [DOI] [PubMed] [Google Scholar]
  • 65.Cárdenes R., Sebastian R., Soto-Iglesias D., Berruezo A., Camara O. Estimation of Purkinje trees from electro-anatomical mapping of the left ventricle using minimal cost geodesics. Med. Image Anal. 2015;24(1):52–62. doi: 10.1016/j.media.2015.05.007. [DOI] [PubMed] [Google Scholar]
  • 66.Barber F., García-Fernández I., Lozano M., Sebastian R. Automatic estimation of Purkinje-myocardial junction hot-spots from noisy endocardial samples: a simulation study. Int. J. Numer. Method Biomed. Eng. 2018;34(7):1–15. doi: 10.1002/cnm.2988. [DOI] [PubMed] [Google Scholar]
  • 67.Szumowski L., Sanders P., Walczak F., Hocini M., Jaïs P., Kepski R. Mapping and ablation of polymorphic ventricular tachycardia after myocardial infarction. J. Am. Coll. Cardiol. 2004;44(8):1700–1706. doi: 10.1016/j.jacc.2004.08.034. [DOI] [PubMed] [Google Scholar]
  • 68.Bänsch D., Oyang F., Antz M., Arentz T., Weber R., Val-Mejias J.E. Successful catheter ablation of electrical storm after myocardial infarction. Circulation. 2003;108(24):3011–3016. doi: 10.1161/01.CIR.0000103701.30662.5C. [DOI] [PubMed] [Google Scholar]
  • 69.Garcia-Bustos V., Sebastian R., Izquierdo M., Rios-Navarro C., Bodí V., Chorro F.J. Changes in the spatial distribution of the Purkinje network after acute myocardial infarction in the pig. PLoS One. 2019;14(2):1–17. doi: 10.1371/journal.pone.0212096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Maruyama M., Kurita T., Kotake Y., Hashiguchi N., Yasuoka R., Ueno M. Early transient recurrence of ventricular fibrillation after catheter ablation of premature ventricular contraction from Purkinje fibers in two patients with myocardial infarction. J. Cardiol. Cases. 2019;19(2):66–69. doi: 10.1016/j.jccase.2018.10.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Lopez-Perez A., Sebastian R., Izquierdo M., Ruiz R., Bishop M., Ferrero J.M. Personalized cardiac computational models: from clinical data to simulation of infarct-related ventricular tachycardia. Front. Physiol. 2019;10(May):1–26. doi: 10.3389/fphys.2019.00580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Peichl P., Čihák R., Koželuhová M., Wichterle D., Vančura V., Kautzner J. Catheter ablation of arrhythmic storm triggered by monomorphic ectopic beats in patients with coronary artery disease. J. Interv. Card. Electrophysiol. 2010;27(1):51–59. doi: 10.1007/s10840-009-9443-2. [DOI] [PubMed] [Google Scholar]
  • 73.Marrouche N.F., Verma A., Wazni O., Schweikert R., Martin D.O., Saliba W. Mode of initiation and ablation of ventricular fibrillation storms in patients with ischemic cardiomyopathy. J. Am. Coll. Cardiol. 2004;43(9):1715–1720. doi: 10.1016/j.jacc.2004.03.004. [DOI] [PubMed] [Google Scholar]
  • 74.Bode K., Hindricks G., Piorkowski C., Sommer P., Janoušek J., Dagres N. Ablation of polymorphic ventricular tachycardias in patients with structural heart disease. Pacing Clin. Electrophysiol. 2008;31(12):1585–1591. doi: 10.1111/j.1540-8159.2008.01230.x. [DOI] [PubMed] [Google Scholar]
  • 75.Baher A.A., Uy M., Xie F., Garfinkel A., Qu Z., Weiss J.N. Bidirectional ventricular tachycardia: ping pong in the his–Purkinje system. Heart Rhythm. 2011;8(4):599–605. doi: 10.1016/j.hrthm.2010.11.038. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Weerasooriya R., Hsu L.F., Scavée C., Sanders P., Hocini M., Cabrera J.A. Catheter ablation of ventricular fibrillation in structurally normal hearts targeting the RVOT and Purkinje ectopy. Herz. 2003;28(7):598–606. doi: 10.1007/s00059-003-2491-y. [DOI] [PubMed] [Google Scholar]
  • 77.Gintant G.A., Limberis J.T., JS McDermott, Wegner C.D., Cox B.F. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J. Cardiovasc. Pharmacol. 2001;37(5):607–618. doi: 10.1097/00005344-200105000-00012. [DOI] [PubMed] [Google Scholar]
  • 78.Cordeiro J.M., Bridge J.H.B., Spitzer K.W. Early and delayed afterdepolarizations in rabbit heart Purkinje cells viewed by confocal microscopy. Cell Calcium. 2001;29(5):289–297. doi: 10.1054/ceca.2000.0192. [DOI] [PubMed] [Google Scholar]
  • 79.Aslanidi O.V., Sleiman R.N., Boyett M.R., Hancox J.C., Zhang H. Ionic mechanisms for electrical heterogeneity between rabbit purkinje fiber and ventricular cells. Biophys. J. 2010;98(11):2420–2431. doi: 10.1016/j.bpj.2010.02.033. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary material

mmc1.pdf (4.6MB, pdf)

RESOURCES